Two Onc Docs ASCO 2025 Preview
May 27, 2025
Get ready for groundbreaking insights from the upcoming ASCO Annual Meeting! Discover cutting-edge research on bladder cancer, including innovative therapies and the role of ctDNA. Explore major advancements in renal cell carcinoma, featuring pivotal trials and new treatment strategies. Plus, dive into the latest in prostate cancer, where prognostic values and the impact of new drugs are making waves. Don’t miss the exciting developments in genitourinary cancers and unique educational sessions that will shape the future of oncology.
AI Snips
Chapters
Transcript
Episode notes
Key Highlights of ASCO 2025 Plenary
- The ASCO 2025 plenary sessions highlight diverse promising therapies across multiple cancers.
- They span polycythemia vera, head and neck, colorectal, breast, and gastric cancers, indicating broad oncology advances.
Bladder Cancer Innovations
- Non-muscle invasive bladder cancer and muscle-invasive bladder cancer show promising new therapies with immunotherapy and photodynamic approaches.
- Novel antibody drug conjugates and ctDNA prognostic markers may reshape treatment paradigms.
RCC Advances at ASCO
- RCC updates include 5-year data on adjuvant pembrolizumab and neoadjuvant combinations.
- Novel agents like HIF2-alpha inhibitors and combinations with immune checkpoint blockers show promise in metastatic RCC.